FDA: Patients Who Respond Well to CML Drug Don’t Have to Stay on It Forever

The FDA updated the label of a cancer drug to include that certain patients with early chronic myeloid leukemia (CML) may be able to stop taking the treatment after they’ve responded well to it over time. The new update indicates that patients with CML who have been taking Tasigna (nilotinib) for 3 years or more, and whose leukemia has responded to treatment based on FDA criteria, may be able to discontinue use of the cancer drug. In the past, patients with CML remained on the drug indefinitely. While musculoskeletal symptoms such as body aches, bone pain and pain in extremities are among the most common side effects, Tasigna’s labeling contains a black-box warning alerting doctors and patients about the risk of abnormal heart rhythm (QT prolongation) and sudden death. Posted December 22, 2017. Via FDA.


Alanna M.

Alanna M. is a graduate of Pace University.

Did you find this article helpful?

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Covid-19: Side Effects of Trump’s Treatments

Covid-19: Side Effects of Trump’s Treatments

President Donald Trump announced (via Twitter, of course) what some considered unthinkable, and others considered inevitable — that he had tested positive for Covid-19. Over the weekend, he received various treatments  — supplements like vitamin D, zinc and melatonin, an experimental antibody combination, an antiviral drug and a powerful anti-inflammatory…

Un-Sheltering Tips for Your Health and Immune System

Un-Sheltering Tips for Your Health and Immune System

As we all emerge from our bubbles of limited contact with others, we are walking straight into the double whammy of flu season and COVID-19 germs. Can your body fight off exposure to the flu and COVID? Your immune system feeds off the basics of life — sleep, movement, food…